Arvinas (ARVN) EPS (Diluted) Growth (3y) (2022 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EPS (Diluted) Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -36.81% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 67.51% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | 60.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 60.16% |
| Mar 31, 2026 | 15.95% |
| Dec 31, 2025 | 14.21% |
| Sep 30, 2025 | 26.14% |
| Jun 30, 2025 | 12.90% |
| Mar 31, 2025 | 44.05% |
| Dec 31, 2024 | 12.05% |
| Sep 30, 2024 | 10.12% |
| Jun 30, 2024 | 21.92% |
| Mar 31, 2024 | -4.69% |
| Dec 31, 2023 | -41.64% |
| Sep 30, 2023 | -7.86% |
| Jun 30, 2023 | -16.36% |
| Mar 31, 2023 | -31.11% |
| Dec 31, 2022 | -33.02% |